An anti-inflammatory drug called ketorolac, given before surgery, can promote long-term survival in animal models of cancer metastasis, a team of scientists has found. The research suggests that flanking chemotherapy with ketorolac or similar drugs -- an approach that is distinct from previous anti-inflammatory cancer prevention efforts -- can unleash anti-tumor immunity.
The findings, published in Journal of Clinical Investigation, also provide a mechanistic explanation for the anti-metastatic effects of ketorolac, previously observed in human Read more
Emory is full of fledgling biomedical proto-companies. Some of them are actual corporations with employees, while others are ideas that need a push to get them to that point. Along with the companies highlighted by the Emory Biotech Consulting Club, Dean Sukhatme’s recent announcement of five I3 Venture research awards gives more examples of early stage research projects with commercial potential.
This is the third round of the I3 awards; the first two were Wow! Read more
Sleeping too little or too much increases the risk of cardiovascular events and death in those with coronary artery disease, according to a new paper from Emory Clinical Cardiovascular Research Institute.
Others have observed a similar U-shaped risk curve in the general population, with respect to sleep duration. The new study, published in American Journal of Cardiology, extends the finding to people who were being evaluated for coronary artery disease.
Arshed Quyyumi, MD and colleagues analyzed Read more
The grant will allow Childrenâ€™s and Emory to expand their research partnership, attract top scientists, and advance research discoveries that will improve the health of children.
Some of the pediatric research conducted in a new building to be built on the Emory campus will focus on cardiology, cancer, vaccines, and new drug discovery. The grant has implications for the city of Atlanta as a growing research community, building on collaborations among Childrenâ€™s Healthcare, Emory, Georgia Institute of Technology, Morehouse School of Medicine, and others.
Fred Sanfilippo, MD, PhD, executive vice president for health affairs at Emory, and Donna W. Hyland, president and CEO of Children’s Healthcare of Atlanta, explained that the new grant, which is the largest single gift ever to Children’s, will have an enormous impact on the two institutions, building on the strong partnership between Emory and Children’s and leading them to become a major pediatric research hub in the Southeast and the nation. Most importantly, it will help in finding cures for some of the most common and devastating childhood diseases.
This fresh approach to wellness marks a new model of healthcare called predictive health, which focuses on defining and maintaining health rather than treating disease.
The Center for Health Discovery and Well Being collects and analyzes physical, medical and lifestyle histories, and up to 50 different blood and plasma tests to create a personalized health action plan for each participant. Participants also act as research partners, as data from their assessments is used to discover and develop predictive markers of health and well being. Those markers are ultimately used to create health-related interventions. Whatâ€™s more, the center is part of a research partnership between Emory and Georgia Tech called the Emory/Georgia Tech Predictive Health Institute.
Located on the 18th floor of the Medical Office Tower (MOT) at Emory University Hospital Midtown, the center occupies an architecturally innovative atmosphere that includes flowing spaces, soothing colors, and a big city view.
Healthy individuals, including those with well-controlled chronic conditions, may enroll in the Center.
Emory Vaccine Center researcher Cynthia Derdeyn and her colleagues have a new paper in PLOS Pathogens that is a reality check for researchers designing possible HIV vaccines. The results come from a collaboration with the Rwanda Zambia HIV Research Group. (Although the patients in this paper are from Zambia only.)
Red and green depict the parts of the HIV envelope protein that mutated in two patients (185F and 205F) in response to pressure from their immune systems.
Recently there has been some excitement over the discovery of robust neutralizing antibodies in patients.
The bottom line, according to Derdeyn’s team: even if a vaccine succeeds in stimulating antibodies that can neutralize HIV, the virus is still going to mutate furiously and may escape those antibodies. To resist HIV, someone’s immune system may need to have several types of antibodies ready to go, their results suggest.
A companion paper in the same issue of PLOS Pathogens from South African scientists has similarly bracing results.
Over the past twenty years, the research partnership between Emory University and the Georgia Institute of Technology has developed into one of the leading bioengineering and biomedical research and educational programs in the nation. In recent years this partnership has resulted in the development of several pieces of diagnostic and medical-assistant technology, with medical experts on the Emory side working with engineers on the Georgia Tech side.
An example of this collaboration is the El-E robot, designed to perform simple tasks such as opening drawers and retrieving objects. Clinicians at Emoryâ€™s School of Medicine and engineers at Georgia Tech created the 5Â½-foot-tall machine, which glides across the floor on wheels and takes direction from a laser pointer that users can control in a variety of ways, depending on their preferences and capabilities. El-E is no mere toy, however: The machine could help patients with significant motor impairments, such as sufferers of ALS, maintain their independence and help relieve physical and financial burdens faced by caregivers.
Another result of the Emory-Georgia Tech collaboration is DETECT, a portable device capable of detecting the earliest stage of Alzheimer’s disease, mild cognitive impairment, in any environment. DETECT has a helmet device that includes an LCD display in a visor, along with a computer and noise-reduction headphones. DETECT gives the patient a battery of words and pictures to assess cognitive abilitiesâ€”reaction time and memory capabilities. The low-cost test takes approximately 10 minutes. The device was co-developed by emergency medicine physician David Wright, and Michelle LaPlaca, a scientist in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory.